Related Experiment Videos
[Basic principles of cost-benefit analysis in long-term treatment of risk factors]
1Abteilung Medizinische Okonomie, Universitätsspital Zürich.
Insights
Statins are a cost-effective choice for preventing cardiovascular disease, offering significant economic benefits in both primary and secondary prevention strategies. This finding aids healthcare decision-makers in optimizing spending for cardiovascular health.
Area of Science:
- Cardiovascular disease prevention
- Health economics
- Pharmacoeconomics
Context:
- Healthcare decision-makers face pressure to manage spending and savings.
- Cardiovascular disease preventive measures require substantial upfront investment.
- Traditional economic evaluations relied on epidemiological models and cholesterol reduction estimates.
Purpose:
- To evaluate the economic benefits of lipid-lowering therapy.
- To assess the cost-effectiveness of statins in cardiovascular prevention.
- To address practical and methodological challenges in pharmacoeconomic evaluations.
Summary:
- Recent outcome studies (4S, CARE, LIPID, WOSCOPS) provide direct economic benefit data for cholesterol reduction.
- Economic evaluations can range from cost-consequence analysis to cost-effectiveness analysis.
- Available data indicate statins are cost-effective for primary and secondary coronary prevention.
Impact:
- Provides evidence for the cost-effectiveness of statins in cardiovascular disease prevention.
- Informs healthcare decision-making regarding lipid-lowering therapies.
- Highlights the economic advantages of preventive cardiovascular measures.
Abstract:
Health care decision makers are increasingly forced to identify and implement the options for potential spendings and savings. Historically, preventive measures for cardiovascular diseases have been scrutinised a great deal. The main reason for this was that substantial financial investments would have to be undertaken long before the clinical benefits were apparent. In the past, most economic evaluations of lipid lowering therapy have been based on models combining logistic regression risk functions from epidemiological cohort studies, such as the Framingham study, with the extent of cholesterol reduction. Recently, however, data from the large controlled outcome studies (4S, CARE, LIPID, WOSCOPS) have been reported which allow a direct estimate of the economic benefits of cholesterol reduction in primary and secondary prevention. The economic evaluation of such therapies can be performed in several ways, from relatively easy cost-consequence analyses to more complex cost-effectiveness analysis. Initial economic analyses of the trials are already available. There are, however, still considerable practical and methodological issues which have to be taken into account in assessing lipid lowering drugs. Available pharmaco-economic data on lipid lowering therapies suggest that statins are a cost-effective option in primary and secondary coronary prevention.